{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:58:14Z","timestamp":1786982294304,"version":"build-2736575974"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"JSPS KAKENHI","award":["JP 25K11666"],"award-info":[{"award-number":["JP 25K11666"]}]},{"DOI":"10.13039\/100017682","name":"Japanese Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017682","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP 22ck0106624h0003"],"award-info":[{"award-number":["JP 22ck0106624h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12185-025-04058-1","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:45:45Z","timestamp":1756287945000},"page":"24-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dasatinib is superior to imatinib in adult Ph\u2009+\u2009ALL: a propensity score-matched analysis of pooled JALSG trial data"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6430-8958","authenticated-orcid":false,"given":"Satoshi","family":"Nishiwaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isamu","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kurahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Dobashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ohtake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Japan Adult Leukemia Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"issue":"3","key":"4058_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24(3):460\u20136.","journal-title":"J Clin Oncol"},{"issue":"11","key":"4058_CR2","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","volume":"65","author":"T O\u2019Hare","year":"2005","unstructured":"O\u2019Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500\u20135.","journal-title":"Cancer Res"},{"issue":"11","key":"4058_CR3","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","volume":"66","author":"JS Tokarski","year":"2006","unstructured":"Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006;66(11):5790\u20137.","journal-title":"Cancer Res"},{"issue":"3","key":"4058_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","volume":"6","author":"S Shen","year":"2020","unstructured":"Shen S, Chen X, Cai J, Yu J, Gao J, Hu S, et al. Effect of Dasatinib vs Imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA Oncol. 2020;6(3):358\u201366.","journal-title":"JAMA Oncol"},{"issue":"4","key":"4058_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ajh.24653","volume":"92","author":"S Fujisawa","year":"2017","unstructured":"Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, et al. Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol. 2017;92(4):367\u201374.","journal-title":"Am J Hematol"},{"issue":"2","key":"4058_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","volume":"6","author":"I Sugiura","year":"2022","unstructured":"Sugiura I, Doki N, Hata T, Cho R, Ito T, Suehiro Y, et al. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022;6(2):624\u201336.","journal-title":"Blood Adv"},{"issue":"6","key":"4058_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000899","volume":"7","author":"S Nishiwaki","year":"2023","unstructured":"Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, et al. High-risk combinations of additional chromosomal abnormalities in Philadelphia chromosome-positive acute lymphoblastic leukemia: JALSG Ph+ALL TKI-SCT study. HemaSphere. 2023;7(6): e899.","journal-title":"HemaSphere"},{"issue":"5","key":"4058_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.27237","volume":"99","author":"S Nishiwaki","year":"2024","unstructured":"Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, et al. Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. Am J Hematol. 2024;99(5):806\u201315.","journal-title":"Am J Hematol"},{"issue":"9","key":"4058_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00277-018-3323-8","volume":"97","author":"Y Hatta","year":"2018","unstructured":"Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, et al. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Ann Hematol. 2018;97(9):1535\u201345.","journal-title":"Ann Hematol"},{"issue":"3","key":"4058_CR10","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1532\/IJH97.06239","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol. 2007;86(3):269\u201374.","journal-title":"Int J Hematol"},{"issue":"12","key":"4058_CR11","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1182\/blood-2004-04-1389","volume":"104","author":"M Towatari","year":"2004","unstructured":"Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2004;104(12):3507\u201312.","journal-title":"Blood"},{"key":"4058_CR12","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"4058_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2307\/2344317","volume":"135","author":"R Peto","year":"1972","unstructured":"Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Seri A (General). 1972;135:185\u2013207.","journal-title":"J R Stat Soc Seri A (General)"},{"key":"4058_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D Cox","year":"1972","unstructured":"Cox D. Regression models and life tables. J R Stat Soc B. 1972;34:187\u2013220.","journal-title":"J R Stat Soc B"},{"issue":"6","key":"4058_CR15","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695\u2013706.","journal-title":"Stat Med"},{"issue":"4","key":"4058_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40(4):381\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4058_CR17","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"4058_CR18","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/jama.2024.4783","volume":"331","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, G\u00f3mez-Almaguer D, et al. Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2024;331(21):1814\u201323.","journal-title":"JAMA"},{"issue":"23","key":"4058_CR19","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1002\/cncr.30231","volume":"122","author":"K Sasaki","year":"2016","unstructured":"Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer. 2016;122(23):3650\u20136.","journal-title":"Cancer"},{"issue":"1","key":"4058_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01221-z","volume":"15","author":"JL Januzzi","year":"2022","unstructured":"Januzzi JL, Garasic JM, Kasner SE, McDonald V, Petrie MC, Seltzer J, et al. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. J Hematol Oncol. 2022;15(1):1.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"4058_CR21","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783\u201396.","journal-title":"N Engl J Med"},{"issue":"15","key":"4058_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","volume":"16","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015;16(15):1547\u201355.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4058_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, G\u00f6kbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57\u201366.","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04058-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04058-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:02:57Z","timestamp":1768834977000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04058-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4058"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04058-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.N. reports honoraria from Otsuka Pharmaceutical Co. Ltd. S.F. reports honoraria from Bristol-Myers-Squibb, Nippon Shinyaku, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Novartis Pharma KK, Janssen, Kyowa Kirin Co., Ltd., AstraZeneca, CSL Behring K.K, Meiji Seika Pharma, AbbVie Inc, Takeda Pharmaceutical Co., Ltd., Asahi Kasei Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Kissei, Pharma Essentia Japan, Genmab, Argenx Japan, Alexion Pharma, Inc., and Chugai Pharmaceutical Co., Ltd. and research funding from Shionogi Co., Ltd., Chugai Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Asahi-Kasei Pharma, and Daiichi Sankyo Co., Ltd. Y.H. reports honoraria from Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and Novartis Pharma KK., and speakers bureau from Kyowa Kirin Co., Ltd. Y.A. reports honoraria from Novartis Pharma KK., Kyowa Kirin Co., Ltd., Abbvie GK, Astellas Pharma Inc., Mochida Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. Y.U. reports honoraria from Otsuka Pharmaceutical Co., Ltd., and Sanofi K.K. N.Dobashi paid expert testimony from Otsuka Pharmaceutical Co., Ltd. T.M. reports research funding from Chugai Pharmaceutical Co., Ltd., and Sumitomo Pharma Co., Ltd., and honoraria from CSL Behring K.K, Asahi Kasei Pharma Corp., Astellas Pharma Inc., Abbvie GK, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma KK., Pfizer Inc., Bristol-Myers Squibb K.K., Janssen Pharmaceutical K.K., Becton Dickinson Company, PharmaEssentia Japan KK and TOPPAN Holdings Inc. I.M. reports honoraria from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co. Ltd., Abbvie GK, Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., Pfizer Japan Inc., Janssen Pharmaceutical K.K., Novartis Pharma KK., Bristol-Myers Squibb, and AstraZeneca plc., research funding from Chugai Pharmaceutical Co., Ltd., Abbvie GK, Genmab K.K., Novartis Pharma KK, and Incyte Japan, and scholarship funds from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., Asahi Kasei Corporation, Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and Abbvie GK. S.Kako reports honoraria from Chugai Pharmaceutical Co., Ltd., Sanofi K.K. and Pfizer Inc. Y.Miyazaki is an Associate Editor for the IJH and reports research funding from Nippon Shinyaku Co., Ltd., Novartis Pharma KK., Abbvie GK, Astellas Pharma Inc., Sumitomo Dainippon Pharma Co., Ltd., SymBio Pharmaceuticals Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., Kyowa Kirin Co., Ltd., Pfizer Inc., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. Ltd., Daiichi Sankyo Co., Ltd., Janssen Pharmaceutical K.K., and Celgene Corp., and honoraria from Sumitomo Dainippon Pharma Co., Ltd. H.K. reports research funding from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Zenyaku Kogyo Co., Ltd., Sumitomo Pharma Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Perseus Proteomics Inc., CURED Co., Ltd., Astellas Pharma Inc., Asahi Kasei Corporation, Abbvie Inc., Nippon Shinyaku, Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Takeda Pharmaceutical Co. Ltd., and honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Daiichi Sankyo Co., Ltd., Astellas Pharma Inc., Abbvie Inc., Nippon Shinyaku Co., Ltd., AstraZeneca plc., Novartis Pharma KK., SymBio Pharmaceuticals Ltd.., Bristol-Myers Squibb K.K., Amgen Inc., Meiji Seika Pharma Co., Ltd., Pfizer Inc., Nippon Kayaku Co., Ltd., and Towa Pharmaceutical Co., Ltd. The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}